TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04856878
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigational drug vancomycin is administered intravenously through a newly inserted peripheral or central venous catheter directly after removal of the 'old' catheters. The investigational drug is administered with a volume of 500ml normal saline (NaCl 0.9%) with a rate of maximal 1g per hour.
Study: NCT05288192
Drug: Suprachoroidal triamcinolone acetonide (SCTA) injection
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suprachoroidal injection of 4mg/0.1ml of triamcinolone acetonide.
Study: NCT05751304
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: (50 patients) will receive calculated dose of intrathecal hyperbaric bupivacaine 0.5 % according to body weight and 5μg Dexametomidine.
Study: NCT05751304
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (50 patients) will receive calculated dose of intrathecal hyperbaric bupivacaine 0.5 % according to body weight and 0.1 mg/kg ketamine.
Study: NCT04466007
Drug: High dose allogeneic mesenchymal stromal cells
Normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic mesenchymal stromal cells derived from adipose tissue administered intramuscularly
Study: NCT04466007
Drug: Low dose allogeneic mesenchymal stromal cells
Normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic mesenchymal stromal cells derived from adipose tissue administered intramuscularly
Study: NCT05334238
Drug: Orelabrutinib
Normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of Orelabrutinib 150mg daily for 1 year, beginning 8 weeks after autologous transplantation
Study: NCT05688085
Drug: Irbesartan High/Amlodipine FDC
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan High/Amlodipine FDC
Study: NCT05688085
Drug: Irbesartan High
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Co-administration of Irbesartan High and Amlodipine
Study: NCT05688085
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Co-administration of Irbesartan High and Amlodipine
Study: NCT04277247
Drug: Botulinum toxin type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: A standardized dose will be injected in each muscle: 25 Units of BTXA in the extensor hallucis longus in 1 site, 50 Units of BTXA in the flexor digitorum brevis in 2 sites and 25 Units of BTXA in the tibialis posterior in 1 site.
Study: NCT05014568
Drug: tapinarof cream, 1%
DrugBank: Tapinarof (DB06083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: applied topically once daily
Study: NCT05640427
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Groups D1 received general anesthesia with intravenous pump of 0. 2μg/kg/h dexmedetomidine to 30min before the end of the operation.Groups D2 received general anesthesia with intravenous pump of 0. 5μg/kg/h dexmedetomidine to 30min before the end of the operation.
Study: NCT05511948
Drug: Hydroquinone Cream
Normalized name: Hydroquinone Cream
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4% Hydroquinone cream, Acella (approved), twice daily for 12 weeks
Study: NCT05044897
Drug: SI-B001
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration weekly by intravenous infusion（QW）.
Study: NCT04648020
Drug: Clonidine HCl Mucoadhesive Buccal Tablet
Normalized name: Clonidine Hydrochloride
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 μg of clonidine per tablet
Study: NCT05067335
Drug: Romosozumab
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive romosozumab in a specified sequence during the treatment Period.
Study: NCT05878067
Drug: ABBV-444
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubricant Eye drops
Study: NCT05309525
Drug: Collagenase Clostridium Histolyticum-Aaes
Normalized name: collagenase clostridium histolyticum-aaes
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects will be injected with up to 0.84 mg of QWO as 12 subcutaneous injections (0.3-mL injection administered as three 0.1-mL aliquots per injection), dependent on the amount of dimples (0.3 ml per dimple).
Study: NCT06563518
Drug: Colgate Cavity Protection
Normalized name: DELTA COMFORT PLUS 2019 AMENITY With Colgate Cavity Protection KIT
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: toothpaste
Study: NCT06564805
Drug: Candida Albicans Antigen Injection
DrugBank: Candida albicans (DB10429)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous administration of Candida albicans antigen
Study: NCT05284643
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be administered intravenously (IV), beginning at a dose of 10 mg/kg every 2-3 weeks until disease progression.
Study: NCT04982796
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: See description of psilocybin-enhanced psychotherapy arm.
Study: NCT06560333
Drug: N0892
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 tablet of Forxiga® 10mg, 1 tablet of Januvia® 100mg and 1 tablet of Glifage XR® 1000mg
Study: NCT05815602
Drug: Ebastine
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized subjects will administer 4 pills of study medication per day during 12 weeks.~Daily administration schedule consists of taking 2 pills in the morning (1 verum, and 1 placebo). In the evening, subjects will take a second dose of both verum and placebo.
Study: NCT05815602
Drug: Duspatalin
DrugBank: Mebeverine (DB12554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized subjects will administer 4 pills of study medication per day during 12 weeks.~Daily administration schedule consists of taking 2 pills in the morning (1 verum, and 1 placebo). In the evening, subjects will take a second dose of both verum and placebo.
Study: NCT06249464
Drug: Lidocaine hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the observation group was given SGB once a day, with 10 sessions as a course of treatment and each side of the body for one course. All the materials included: 1) 1.5ml of 2% Lidocaine hydrochloride injection (1ml: 0.5mg), Vitamin B12 Injection 500ug (1ml: 0.5g), the 5 ml disposable syringe and the sterile disposable dental injection needles. The specific operation procedure was as follows\[16\]: The operator stood at the patient\&#39;s block side, and the patient was placed in the supine position, with the head leaning 45 degrees toward the contralateral side of the block side. After routine disinfection of the skin, a paratracheal approach was adopted, which was, 2.5cm above the sternoclavicular joint and 1.5cm outside the midline of the neck.
Study: NCT04494789
Drug: Fludrocortisone Acetate
Normalized name: Fludrocortisone Acetate
DrugBank: Fludrocortisone (DB00687)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mcg
Study: NCT04494789
Drug: Fludrocortisone Acetate
Normalized name: Fludrocortisone Acetate
DrugBank: Fludrocortisone (DB00687)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mcg
Study: NCT04494789
Drug: Fludrocortisone Acetate
Normalized name: Fludrocortisone Acetate
DrugBank: Fludrocortisone (DB00687)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mcg
Study: NCT05639959
Drug: Mometasone Nasal 50 Mcg/Inh Nasal Spray
Normalized name: mometasone nasal 50 mcg/inh nasal spray
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone furoate nasal spray effectively reduced total and individual symptoms scores in patients with allergic rhinitis.
Study: NCT04088903
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: \>Daratumumab 16 mg/kg intravenous weekly for 8 weeks and then every other week for 2 doses.
Study: NCT03493152
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: mTOR inhibitor
Study: NCT05962021
Drug: Toripalimab plus Chemotherapy
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy was administered on a 21-day regimen for 3 cycles, with Toripalimab (240mg, d1), carboplatin (AUC=5, d1) + pemetrexed (500 mg/m2, d1) for patients with lung adenocarcinoma and carboplatin (AUC=5, d1) + albumin-bound paclitaxel (260 mg/m2, d1) for patients with other subtypes.
Study: NCT05667038
Drug: Probiotic
Normalized name: PROBIOTIC
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The probiotics sachet contains a granular powder with 6 microorganism strains (30 × 109 CFU/gram): Lactobacillus acidophilus BCMC®12130, Lactobacillus casei subsp BCMC®12313, Lactobacillus lactis BCMC®12451, Bifidobacterium bifidum BCMC®02290, Bifidobacterium infantis BCMC®02129, and Bifidobacterium longum BCMC®02120.~The drug is consumed orally, two sachets per day, by dissolving the sachet content in a glass of room-temperature water, one before breakfast and one before the last meal, for three months length.
Study: NCT06643403
Drug: Oxygen 100% Gas for Inhalation
Normalized name: Oxygen 100% gas for inhalation
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SAUERSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~min. 95.5%, breathing for max. 45 minutes
Study: NCT06154590
Drug: Method(s)1 Attribution
Normalized name: menthol 1 MG [Luden's]
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention(s): Attribution defines the relationship between the adverse event and the investigational agent(s)/intervention. Assign the appropriate category code of attribution Codes: 1-5, Descriptor, Unrelated, Unlikely, Possible, Probable, Definite.~Definitions: Use the Adverse Event Dose Units- Indicate the dosing units (e.g., mg) administered to the patient. TAC, Reporting Group: Participants with Disease, Description: Presence of Disease as Defined by positive reference test.~Dosage Form: 1mg Anastrozole, given once daily. 20 mg NOLVADEX (tamoxifen citrate) tablet given once daily, (the 20 mg NOLVADEX (tamoxifen citrate) tablet is bioequivalent to the 10 mg NOLVADEX. (tamoxifen citrate) tablets.)
Study: NCT06079983
Drug: Gemcitabine hydrochloride for injection
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered according to protocol, as one option for investigator's choice (determined before randomization).
Study: NCT06079983
Drug: Vinorelbine tartrate injection
Normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered according to protocol, as one option for investigator's choice (determined before randomization).
Study: NCT06079983
Drug: Paclitaxel for injection (albumin-bound type)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered according to protocol, as one option for investigator's choice (determined before randomization).
Study: NCT06079983
Drug: Docetaxel injection
Normalized name: docetaxel Injection
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered according to protocol, as one option for investigator's choice (determined before randomization).
Study: NCT06079983
Drug: Eribulin mesylate injection
Normalized name: Eribulin Mesylate Injection
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered according to protocol, as one option for investigator's choice (determined before randomization).
Study: NCT06557304
Drug: BTK inhibitor
Normalized name: BTK inhibitor CC-292
DrugBank: Spebrutinib (DB11764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients with treatment naive or R/R CLL who treatment with BTK inhibitor
Study: NCT06332157
Drug: Remimazolam besylate
Normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In Remimazolam group, anesthesia was induced with remimazolam besylate at a rate of 6mg/min and maintained with 1.0-2.0mg/min until the end of surgery.
Study: NCT06332157
Drug: Propofol Injection Emulsion
Normalized name: propofol lipid emulsion Injection
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In Propofol group, anesthesia was induced with propofol injection emulsion at a rate of 2mg/kg and maintained with 6-8mg/kg/h until the end of surgery.
Study: NCT06654193
Drug: Allogeneic HB-adMSCs
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic HB-adMSCs
Study: NCT06655480
Drug: [ARNI + SGLTi + AMR]
DrugBank: Lepirudin (DB00001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Empagliflozin 10mg tablet, Valsartan+Sacubitril 100-200-400 mg tablet, Finerenone 20-40 mg tablet
Study: NCT04951349
Drug: GX-03
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same dosage used in Bactroban Nasal studies.
Study: NCT04951349
Drug: Petrolatum ointment
Normalized name: GERI PROTECT Petrolatum Ointment
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscous ointment similar in form to study drug.
Study: NCT05904717
Drug: PXS-4728 (A)
Normalized name: PX-102
DrugBank: PXS-4728A free base (DB19177)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive once daily (QD) for period of 12 weeks
Study: NCT04845139
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab given intraventricularly
Study: NCT05648708
Drug: Bupivacaine and prilocaine hydrochloride
Normalized name: Prilocaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigators will perform a combined adductor canal \& sciatic nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
Study: NCT05648708
Drug: Bupivacaine and prilocaine hydrochloride
Normalized name: Prilocaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigators will perform a combined femoral \& sciatic nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
Study: NCT05733689
Drug: NIVOLUMAB (alone or when added to a regimen above)
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * 240 mg IV on Day 1 every 14 days, or~* 360 mg IV on Day 1 every 21 days, or~* 480 mg IV on Day 1 every 28 days
Study: NCT05733689
Drug: PEMBROLIZUMAB (alone or when added to a regimen above)
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * 200 mg IV on Day 1 every 21 days, or~* 400 mg IV on Day 1 every 42 days
Study: NCT06165991
Drug: Liposomal bupivacaine, Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block complex PCIA;~1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block combined with drainage tube analgesia technique combined with PCIA
Study: NCT06632080
Drug: Substance P
Normalized name: Substance P
DrugBank: Substance P (DB19198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive a continuous intravenous infusion of 20 mL of substance P (1.5 pmol/kg/min) over 20 minutes.
Study: NCT05745714
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT05745714
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral
Study: NCT05745714
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral/intravenous
Study: NCT05745714
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous
Study: NCT05745714
Drug: intrathecal chemotherapy
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
Study: NCT00000806
Drug: Telinavir
Normalized name: Telinavir
DrugBank: Telinavir (DB12178)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06404034
Drug: Gallium Maltolate
Normalized name: Gallium maltolate
DrugBank: Gallium maltolate (DB05420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GaM will be provided as 500 mg capsules and will be self-administered once daily by mouth at the assigned dose level on a 28-day cycle (one cycle is 28 days) on an empty stomach. GaM should be taken at least 60 minutes before a meal and at least two hours after a meal. Liquids are allowed
Study: NCT06266546
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic tranexamic acid will be instilled via endobronchial route in all patients undergoing transbronchial cryobiopsy. The medication will be administered through the bronchoscope one minute prior to the cryobiopsy. 500 mg of TXA diluted in 10 ml of saline and the procedure would be carried out as usual.
Study: NCT05323656
Drug: Setanaxib
Normalized name: Setanaxib
DrugBank: Setanaxib (DB16869)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets, 400 mg per tablet
Study: NCT04970914
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
Study: NCT04970914
Drug: Penpulimab
Normalized name: Penpulimab
DrugBank: Penpulimab (DB16747)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penpulimab 200 mg administered intravenously every 3 weeks.
Study: NCT05067582
Drug: L1-79
Normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tyrosine hydroxylase inhibitor
Study: NCT06357104
Drug: Sertraline Hydrochloride
Normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline is taken in the morning for 150 mg per day.
Study: NCT06357104
Drug: Clonazepam
Normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonazepam is taken in the morning for 1 mg per day.
Study: NCT06357104
Drug: Alprazolam
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprazolam is introduced near the end of the primary efficacy endpoint for 0.4 mg per night.
Study: NCT06357104
Drug: Metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol is introduced at the secondary efficacy endpoint starting with 47.5 mg per night and increase to 95 mg per night.
Study: NCT06357104
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine is taken throughout the trial with 7.5 mg per night at first, and increases to 10 mg per night after the cocktail therapy.
Study: NCT06357104
Drug: Sacubitril Valsartan Sodium Hydrate
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sacubitril valsartan sodium is introduced in the secondary efficacy endpoint with 100 mg per day.
Study: NCT06341335
Drug: cadonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv, q3w
Study: NCT06341335
Drug: pulocimab
Normalized name: Pulocimab
DrugBank: Pulocimab (DB18938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv, q3w
Study: NCT06341335
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: iv, q3w
Study: NCT05006664
Drug: Adcetris 50 MG Injection
Normalized name: Adcetris 50 MG Injection
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment by study drug Brentuximab Vedotin (Adcetris) in combination with CHEP.
Study: NCT05006664
Drug: Endoxan
Normalized name: Endoxana
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment by study drug Cyclophosphamide (Endoxan) in combination.
Study: NCT05006664
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment by study drug Etoposide in combination.
Study: NCT05006664
Drug: Prednisone tablet
Normalized name: Prednisone Tablets
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment by study drug Prednisone in combination.
Study: NCT00467441
Drug: VSF-173
Normalized name: VSF-173
DrugBank: VSF-173 (DB05753)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000901
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000901
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00000901
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05629390
Drug: Lotilaner
Normalized name: lotilaner
DrugBank: Lotilaner (DB17992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotilaner Ophthalmic Solution
Study: NCT05629390
Drug: Vehicle Control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle of TP-03 ophthalmic solution